Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Envoy Medical, Inc.COCH · Entity 7161 | Director · Chief Executive Officer | June 19, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Envoy Medical, Inc.
Report date June 19, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.63 · Expires 2036-06-19 | Direct | 1,000,000 |
Reported balance
After 2026-06-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-19 · Grant · Acquired 1,000,000 · Balance 1,000,000 F3: Options to purchase 250,000 shares vest on 6/19/27, and 750,000 shares vest pro rata on the 19th of each month thereafter for 36 consecutive months. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.40 · Expires 2033-10-15 | Direct | 879,749 |
Reported balance
Holding disclosure · report date 2026-06-19 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 879,749 F1: Options to purchase 659,811 shares vest on 10/15/2023, and 219,938 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.53 · Expires 2036-02-05 | Direct | 200,000 |
Reported balance
Holding disclosure · report date 2026-06-19 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 200,000 F2: Options to purchase 50,000 shares vest on 2/5/2027, and 150,000 shares vest pro rata on the 5th of each month thereafter for 36 consecutive months. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2030-06-18 | Direct | 1,000,000 |
Reported balance
After 2026-06-19 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-06-19 · Grant · Acquired 1,000,000 · Balance 1,000,000 F7: Each restricted stock unit represents a contingent right to receive one share of Envoy Medical, Inc. Class A Common Stock. F8: All restricted stock units subject to the RSU Award Grant Notice dated June 19, 2026, will vest as of the date of the official notification by the U.S. Food and Drug Administration (FDA) that it has granted approval (including approval with conditions) for its Acclaim cochlear implant, provided that such announcement occurs during the performance period beginning June 19, 2026 and ending on June 18, 2030. |
| Class A Common StockSEC Table I · non-derivative | Direct | 329,946 |
Reported balance
Holding disclosure · report date 2026-06-19 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 329,946 |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2028-09-29 | Direct | 110,987 |
Reported balance
Holding disclosure · report date 2026-06-19 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 110,987 F4: Fully exercisable. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.40 | Direct | 37,500 |
Reported balance
Holding disclosure · report date 2026-06-19 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 37,500 F4: Fully exercisable. F5: The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.40 | Direct | 62,500 |
Reported balance
Holding disclosure · report date 2026-06-19 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 62,500 F4: Fully exercisable. F6: The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device. |
Filing footnotes · ownership attribution and instrument terms
F1: Options to purchase 659,811 shares vest on 10/15/2023, and 219,938 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months.
F2: Options to purchase 50,000 shares vest on 2/5/2027, and 150,000 shares vest pro rata on the 5th of each month thereafter for 36 consecutive months.
F3: Options to purchase 250,000 shares vest on 6/19/27, and 750,000 shares vest pro rata on the 19th of each month thereafter for 36 consecutive months.
F4: Fully exercisable.
F5: The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device.
F6: The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device.
F7: Each restricted stock unit represents a contingent right to receive one share of Envoy Medical, Inc. Class A Common Stock.
F8: All restricted stock units subject to the RSU Award Grant Notice dated June 19, 2026, will vest as of the date of the official notification by the U.S. Food and Drug Administration (FDA) that it has granted approval (including approval with conditions) for its Acclaim cochlear implant, provided that such announcement occurs during the performance period beginning June 19, 2026 and ending on June 18, 2030.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 19, 2026 Filed Jun 23, 2026 22:28 UTC | Envoy Medical, Inc. COCH · Entity 7161 | GrantRestricted Stock Units · Derivative | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000100 · form4.xml · derivative · entry 8 Lucas Brent T. · CIK 0001994382 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Class A Common Stock · 1,000,000 shares Expires 2030-06-18 F7 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Envoy Medical, Inc. Class A Common Stock. F8 · derivative.exercise_date: All restricted stock units subject to the RSU Award Grant Notice dated June 19, 2026, will vest as of the date of the official notification by the U.S. Food and Drug Administration (FDA) that it has granted approval (including approval with conditions) for its Acclaim cochlear implant, provided that such announcement occurs during the performance period beginning June 19, 2026 and ending on June 18, 2030. Read SEC document |
| June 19, 2026 Filed Jun 23, 2026 22:28 UTC | Envoy Medical, Inc. COCH · Entity 7161 | GrantStock Option (right to buy) · Derivative | 1,000,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0000914190-26-000100 · form4.xml · derivative · entry 4 Lucas Brent T. · CIK 0001994382 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Class A Common Stock · 1,000,000 shares Expires 2036-06-19 F3 · derivative.exercise_date: Options to purchase 250,000 shares vest on 6/19/27, and 750,000 shares vest pro rata on the 19th of each month thereafter for 36 consecutive months. Read SEC document |
| May 29, 2026 Filed Jun 4, 2026 20:28 UTC | Envoy Medical, Inc. COCH · Entity 7161 | GrantClass A Common Stock | 32,856 | $0.60 | $19,680.74 |
DisclosureSEC source: 0000914190-26-000095 · form4.xml · nonDerivative · entry 1 Lucas Brent T. · CIK 0001994382 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 329,946 F1 · kind: These shares were acquired under the Envoy Medical, Inc. Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:45 UTC | Envoy Medical, Inc. COCH · Entity 7161 | PurchaseWarrant (right to buy) · Derivative | 62,500 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0000914190-26-000024 · form4.xml · derivative · entry 6 Lucas Brent T. · CIK 0001994382 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,500 Underlying: Class A Common Stock · 62,500 shares Expires not disclosed F4 · derivative.exercise_date: Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants. F6 · derivative.expiration_date: The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:45 UTC | Envoy Medical, Inc. COCH · Entity 7161 | PurchaseWarrant (right to buy) · Derivative | 37,500 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0000914190-26-000024 · form4.xml · derivative · entry 5 Lucas Brent T. · CIK 0001994382 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Class A Common Stock · 37,500 shares Expires not disclosed F4 · derivative.exercise_date: Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants. F5 · derivative.expiration_date: The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:45 UTC | Envoy Medical, Inc. COCH · Entity 7161 | PurchaseClass A Common Stock | 62,500 | $0.40 | $25,000.00 |
DisclosureSEC source: 0000914190-26-000024 · form4.xml · nonDerivative · entry 1 Lucas Brent T. · CIK 0001994382 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 297,090 Read SEC document |
| February 05, 2026 Filed Feb 9, 2026 22:45 UTC | Envoy Medical, Inc. COCH · Entity 7161 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0000914190-26-000014 · form4.xml · derivative · entry 4 Lucas Brent T. · CIK 0001994382 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Class A Common Stock · 200,000 shares Expires 2036-02-05 F3 · derivative.exercise_date: Options to purchase 50,000 shares vest on 2/5/2027, and 150,000 shares vest pro rata on the 5th of each month thereafter for 36 consecutive months. Read SEC document |
| November 28, 2025 Filed Dec 10, 2025 22:49 UTC | Envoy Medical, Inc. COCH · Entity 7161 | GrantClass A Common Stock | 18,105 | $0.71 | $12,908.87 |
DisclosureSEC source: 0000914190-25-000054 · form4.xml · nonDerivative · entry 1 Lucas Brent T. · CIK 0001994382 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234,590 F1 · kind: These shares were acquired under the Envoy Medical, Inc. Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| May 30, 2025 Filed Jun 10, 2025 00:58 UTC | Envoy Medical, Inc. COCH · Entity 7161 | GrantClass A Common Stock | 7,742 | $1.29 | $10,008.08 |
DisclosureSEC source: 0001062993-25-011296 · form4.xml · nonDerivative · entry 2 Lucas Brent T. · CIK 0001994382 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,485 F1 · kind: These shares were acquired under the Envoy Medical, Inc. Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 21:10 UTC | Envoy Medical, Inc. COCH · Entity 7161 | PurchaseWarrant (right to buy) · Derivative | 16,694 | $0.06 Strike: $11.50 | $1,001.64 |
DisclosureSEC source: 0001062993-24-020597 · form4.xml · derivative · entry 5 Lucas Brent T. · CIK 0001994382 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,987 Underlying: Class A Common Stock · 16,694 shares Expires 2028-09-29 F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 21:10 UTC | Envoy Medical, Inc. COCH · Entity 7161 | PurchaseWarrant (right to buy) · Derivative | 94,293 | $0.06 Strike: $11.50 | $5,186.12 |
DisclosureSEC source: 0001062993-24-020597 · form4.xml · derivative · entry 4 Lucas Brent T. · CIK 0001994382 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,293 Underlying: Class A Common Stock · 94,293 shares Expires 2028-09-29 F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 30, 2024 Filed Jun 10, 2025 00:58 UTC | Envoy Medical, Inc. COCH · Entity 7161 | GrantClass A Common Stock | 5,165 | $1.94 | $10,020.10 |
DisclosureSEC source: 0001062993-25-011296 · form4.xml · nonDerivative · entry 1 Lucas Brent T. · CIK 0001994382 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 208,743 F1 · kind: These shares were acquired under the Envoy Medical, Inc. Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 20:06 UTC | Envoy Medical, Inc. COCH · Entity 7161 | OtherClass A Common Stock | 10,176 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-013065 · form4.xml · nonDerivative · entry 2 Lucas Brent T. · CIK 0001994382 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Family Education Trust Disclosed balance after: 12,720 F1 · shares: Pro rata distribution from Cornerstone Growth Group, LP and Cornerstone Growth Group II, LP, of which the reporting person was a non-managing member and did not have voting, dispositive or other rights. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 20:06 UTC | Envoy Medical, Inc. COCH · Entity 7161 | OtherClass A Common Stock | 74,784 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-013065 · form4.xml · nonDerivative · entry 1 Lucas Brent T. · CIK 0001994382 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,615 F1 · shares: Pro rata distribution from Cornerstone Growth Group, LP and Cornerstone Growth Group II, LP, of which the reporting person was a non-managing member and did not have voting, dispositive or other rights. Read SEC document |
| November 21, 2023 Filed Nov 24, 2023 21:09 UTC | Envoy Medical, Inc. COCH · Entity 7161 | PurchaseClass A Common Stock | 2,380 | $0.92 | $2,189.60 |
DisclosureSEC source: 0001062993-23-021438 · form4.xml · nonDerivative · entry 2 Lucas Brent T. · CIK 0001994382 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,831 Read SEC document |
| November 21, 2023 Filed Nov 24, 2023 21:09 UTC | Envoy Medical, Inc. COCH · Entity 7161 | PurchaseClass A Common Stock | 10,000 | $0.98 | $9,800.00 |
DisclosureSEC source: 0001062993-23-021438 · form4.xml · nonDerivative · entry 1 Lucas Brent T. · CIK 0001994382 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,451 Read SEC document |
| October 15, 2023 Filed Oct 17, 2023 21:25 UTC | Envoy Medical, Inc. COCH · Entity 7161 | GrantStock Option (right to buy) · Derivative | 879,749 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001062993-23-019479 · form4.xml · derivative · entry 5 Lucas Brent T. · CIK 0001994382 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 879,749 Underlying: Class A Common Stock · 879,749 shares Expires 2033-10-15 F1 · derivative.exercise_date: Options to purchase 659,811 shares vest on 10/15/2023, and 219,938 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.